Targeting fat-tissue hormone may lead to type 2 diabetes treatment

The preclinical development of a therapeutic that could potentially be used to treat type 2 diabetes, fatty liver disease, and other metabolic diseases has been outlined in a new report. The researchers developed an antibody that improves glucose regulation and reduces fatty liver in obese mice by targeting a hormone in adipose (fat) tissue called aP2 (also known as FABP4).